
Next-gen COVID-19 vaccine good in preclinical tests
In contrast to injectable vaccines, the nasal jab seems capablet to induce mucosal immunity which is crucial to eliminate the virus instead only...

Cellectis and Cytovia in US$760m licence deal
Cytovia Therapeutics, Inc. and French Cellectis SAS have struck a licence deal to combine their different expertises in allogenic cancer cell...

LSP reports first closing of dementia fund
The LSP Dementia Fund is the first fund globally dedicated to fight neurodegenerative diseases with help of drug and medtech solutions. The fund will...

Roche in take-over deal with GenMark Diagnostics
The US$1.8bn cash merger – US$ 24.05 per share – is set to close in Q2/2021. The price represents a premium of approximately 43% to GenMark’s...

Novel COVID antibody enters clinical testing
In contrast to existing COVID-19 treatments, the safety design of COR-101 is optimised for the treatment of hospitalized COVID-19 patients with...

Two companies aim for 2nd-gen COVID vaccines
As scientific papers provide hints that mutants of SARS-CoV-2 that carry the N501Y and E484K mutations are able to reproduce more rapidly as the...

Media hype on Denmark’s decision to halt AZD1222 vaccination
Since Denmark suspended vaccination with AstraZeneca’s bashed Covid-19 vaccine, AZD1222 is facing questions over its safety. Denmark’s...